Myriad Genetics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.11-09

Myriad Genetics (NASDAQ:MYGN) Third Quarter 2024 Results Key Financial Results Revenue: US$213.3m (up 11% from 3Q 2023). Net loss: US$22.1m (loss narrowed by 64% from 3Q 2023). US$0.24 loss per share...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482944038?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","is_english":true,"pubTime":"2024-11-09 20:06","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2482944038","market":"us","top_or_hot":-1,"title":"Myriad Genetics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags","media":"Simply Wall St.","content":"<div>\n<p>Myriad Genetics (NASDAQ:MYGN) Third Quarter 2024 Results\nKey Financial Results\n\nRevenue: US$213.3m (up 11% from 3Q 2023).\nNet loss: US$22.1m (loss narrowed by 64% from 3Q 2023).\nUS$0.24 loss per share...</p>\n\n<a href=\"https://finance.yahoo.com/news/myriad-genetics-third-quarter-2024-120640628.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Myriad Genetics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMyriad Genetics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-09 20:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/myriad-genetics-third-quarter-2024-120640628.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Myriad Genetics (NASDAQ:MYGN) Third Quarter 2024 Results\nKey Financial Results\n\nRevenue: US$213.3m (up 11% from 3Q 2023).\nNet loss: US$22.1m (loss narrowed by 64% from 3Q 2023).\nUS$0.24 loss per share...</p>\n\n<a href=\"https://finance.yahoo.com/news/myriad-genetics-third-quarter-2024-120640628.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYGN","symbol_name":"万基遗传","start_time":0,"source_url":"https://finance.yahoo.com/news/myriad-genetics-third-quarter-2024-120640628.html","article_id":"2482944038","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482944038","pubTimestamp":1731154000,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"NasdaqGS:MYGN Earnings and Revenue Growth November 9th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 1.2%. Earnings per share  missed analyst estimates by 6.2%.Looking ahead, revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.The company's shares are down 3.2% from a week ago.Don't forget that there may still be risks. For instance, we've identified   4 warning signs for Myriad Genetics  that you should be aware of.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MYGN":"万基遗传"},"translate_title":"Myriad Genetics 2024年第三季度收益：收入超出预期，每股收益滞后","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":1},"content_text":"Myriad Genetics (NASDAQ:MYGN) Third Quarter 2024 Results\nKey Financial Results\n\nRevenue: US$213.3m (up 11% from 3Q 2023).\nNet loss: US$22.1m (loss narrowed by 64% from 3Q 2023).\nUS$0.24 loss per share (improved from US$0.75 loss in 3Q 2023).\n\n\n\n\n  NasdaqGS:MYGN Earnings and Revenue Growth November 9th 2024\n \n\nAll figures shown in the chart above are for the trailing 12 month (TTM) period\nMyriad Genetics Revenues Beat Expectations, EPS Falls Short\n Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) missed analyst estimates by 6.2%. \n Looking ahead, revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. \nPerformance of the American Biotechs industry.\n The company's shares are down 3.2% from a week ago. \nRisk Analysis\n Don't forget that there may still be risks. For instance, we've identified   4 warning signs for Myriad Genetics  that you should be aware of. \nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482944038"}